Discovery of Drug Targets for Heart Failure with Preserved and Reduced Ejection Fraction
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Savarese G, Becher P, Lund L, Seferovic P, Rosano G, Coats A
. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022; 118(17):3272-3287.
DOI: 10.1093/cvr/cvac013.
View
2.
Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M
. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17):e263-e421.
DOI: 10.1016/j.jacc.2021.12.012.
View
3.
Shah S, Borlaug B, Kitzman D, McCulloch A, Blaxall B, Agarwal R
. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020; 141(12):1001-1026.
PMC: 7101072.
DOI: 10.1161/CIRCULATIONAHA.119.041886.
View
4.
Trajanoska K, Bherer C, Taliun D, Zhou S, Richards J, Mooser V
. From target discovery to clinical drug development with human genetics. Nature. 2023; 620(7975):737-745.
DOI: 10.1038/s41586-023-06388-8.
View
5.
Rasooly D, Peloso G, Pereira A, Dashti H, Giambartolomei C, Wheeler E
. Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure. Nat Commun. 2023; 14(1):3826.
PMC: 10333277.
DOI: 10.1038/s41467-023-39253-3.
View